Mass General Brigham investigators led a nationwide study that found that financial hardship, food insecurity, lack of healthcare access, and other social risk factors are linked to higher risks of long COVID.

Long COVID includes a wide range of symptoms that present or persist three or more months after SARS-CoV-2 infection. Although in recent years researchers have gained greater insight into the prevalence, symptoms and effects of long COVID through the longitudinal Researching COVID to Enhance Recovery (RECOVER) Initiative, social risk factors for developing long COVID remain incompletely understood. In a new analysis of the RECOVER-Adult cohort, Mass General Brigham researchers found a two- to three-times higher risk of long COVID in those with social risk factors, including financial hardship, food insecurity, experiences of medical discrimination, and skipped medical care due to cost. Findings are published in Annals of Internal Medicine.

"During the pandemic, we saw the overwhelming role that social risk factors played in determining who was infected with COVID-19 and what the severity and mortality from disease was," said lead author Candace Feldman, MD, MPH, ScD, of the Division of Rheumatology, Inflammation and Immunity at Brigham and Women's Hospital (BWH), a founding member of the Mass General Brigham healthcare system. "We wanted to understand whether those risk factors also play a significant role in the longer-term, chronic symptoms that can affect people months and even years after SARS-CoV-2 infection."

In this study, the researchers analyzed 3,700 participants from the RECOVER-Adult cohort, who had a SARS-CoV-2 infection during the Omicron variant outbreak, completed a baseline survey about social and economic factors at the time of infection, and completed a six-month follow-up survey assessing long COVID symptoms. The RECOVER-Adult participants were from 33 states, Washington, D.C., and Puerto Rico, and joined the study between October 2021 and November 2023.

In the baseline survey, the researchers assessed four major individual-level social risk factors: economic instability, education and language access barriers, health care access and quality challenges, and lack of social and community support using a series of questions and previously validated surveys. They also used ZIP code data to study area-level measures of risk, like household crowding.

After adjusting for variables including hospitalization for SARS-CoV-2 infection (as a marker of disease severity), vaccination history, pregnancy status, age, sex, race and ethnicity, the researchers found significant associations between nearly all the individual-level social risk factors studied and increased risk of developing long COVID. Furthermore, a greater number of social risk factors conferred a higher risk of long COVID. Living in areas with more household crowding was also associated with a greater risk of long COVID.

There was a significantly higher burden of social risk factors among racially or ethnically minoritized groups. However, the researchers found that social risk factors appeared to affect white, Black and Hispanic people's risks of long COVID similarly.

Going forward, RECOVER Initiative researchers hope to determine whether these findings extend to children with long COVID and whether certain long COVID symptoms may be linked to specific social risk factors. They also hope to study symptoms of COVID-19 lasting a year or longer to better understand how social factors might contribute to these symptoms' persistence.

"While rates of COVID-19 have decreased, long COVID is a chronic disease that many people still suffer from," said senior author Elizabeth Karlson, MD, MS, of the Division of Rheumatology, Inflammation and Immunity at BWH. "As with other chronic diseases, many different parts of people's social environment influence long COVID risk. Future interventions must address these factors to effectively reduce adverse outcomes among people with high burden of social risk factors."

Authorship: In addition to Feldman and Karlson, Mass General Brigham authors include Leah Santacroce, Ingrid V. Bassett, Tanayott Thaweethai, Yuri Quintana, Bruce D. Levy, and Cheryl R. Clark.

Additional authors include Radica Alicic, Rachel Atchley-Challenner, Alicia Chung, Mark P. Goldberg, Carol R. Horowitz, Karen B. Jacobson, J. Daniel Kelly, Stacey Knight, Karen Lutrick, Praveen Mudumbi, Sairam Parthasarathy, Heather Prendergast, Nasser Sharareh, Judd Shellito, Zaki A. Sherif, Brittany D. Taylor, Emily Taylor, Joel Tsevat, Zanthia Wiley, Natasha J. Williams, Lynn Yee, Lisa Aponte-Soto, Jhony Baissary, Jasmine Berry, Alexander W. Charney, Maged M. Costantine, Alexandria M. Duven, Nathaniel Erdmann, Kacey C. Ernst, Elen M. Feuerriegel, Valerie J. Flaherman, Minjoung Go, Kellie Hawkins, Vanessa Jacoby, Janice John, Sara Kelly, Elijah Kindred, Adeyinka Laiyemo, Emily B. Levitan, Jennifer K. Logue, Jai G. Marathe, Jeffrey N. Martin, Grace A. McComsey, Torri D. Metz, Tony Minor, Aoyjai P. Montgomery, Janet M. Mullington, Igho Ofotukun, Megumi J. Okumura, Michael J. Peluso, Kristen Pogreba-Brown, Hengameh Raissy, Johana M. Rosas, Upinder Singh, Timothy VanWagoner.

Disclosures: Feldman receives grant support to her institution for health equity research and consults for several organizations on unrelated content. Knight receives research funding from Janssen. Alicic, Parthasarathy, Aponte-Soto, Singh, Levitan, and Mullington receive NIH or other research funding or consulting support unrelated to this manuscript.

Funding: This study was funded in part by the National Institutes of Health (OTA OT2HL161841, OTA OT2HL161847, and OTA OT2HL156812).

Read more …Researchers discover key social factors that triple long COVID risk

Lupus is a "classic" autoimmune disease.

It causes the immune system's first-line viral defenses -- known as interferons -- to attack the body. Nearly every organ is at risk, leading to conditions like kidney and heart disease.

But unlike many other autoimmune or chronic illnesses, lupus can improve as patients reach their 60s and 70s.

"I see my younger lupus patients in their 20s, 30s, and 40s every few months, monitoring them closely for signs of severe disease, but many of my older patients just once a year to touch base," said Sarah Patterson, MD, assistant professor of medicine in the division of rheumatology at UCSF. "If patients make it through those risky decades, they sometimes see a dramatic improvement."

Now, Patterson and colleagues have published a study in Science Translational Medicine that reveals how this works.

By analyzing blood samples from patients across the age spectrum, the team discovered that aging turns down the activity of certain immune genes in people with lupus, leading to fewer interferons and other inflammatory proteins in the body.

The study found that in healthy adults, inflammation-related genes and proteins rose slowly over the years, a process that has been dubbed "inflammaging." In patients with lupus, however, the expression of these genes and proteins were abnormally high in mid-life but decreased as the decades went by.

"Inflammaging seemed to be reversed in the lupus patients," said Chaz Langelier, MD, PhD, associate professor of medicine at UCSF and senior author of the paper. "But it wasn't fully reversed. The lupus patients still had a greater level of inflammatory signaling compared to healthy adults in older age."

That reversal reflected what Patterson has seen in her patients -- a return to something approaching healthy older age.

Next, the team intends to test whether drugs that block interferons are more or less effective in lupus patients at different ages. They also hope to extend the approach to understand other inflammation-related conditions, such as rheumatoid arthritis, COPD, and atherosclerosis.

Authors: Other UCSF authors are Rithwik Narendra, Hoang Van Phan, Ana Almonte-Loya, Emily C. Lydon, MD, Christina Love, Michiko Shimoda, PhD, Padmini Deosthale, MS, Lenka Maliskova, Walter Eckalbar, PhD, Gabriela K. Fragiadakis, PhD, Jinoos Yazdany, MD, MPH, Maria Dall'Era, MD, Patricia Katz, PhD, Chun Jimmie Ye, PhD, and Marina Sirota, PhD. For a complete author list see the paper.

Funding: This work was funded by the National Institutes of Health (R01 AR069616, K23AT011768, P30 AI027763), the US Centers for Disease Control and Prevention (CDC), and the Chan Zuckerberg Biohub.

Read more …Lupus often fades with age. Scientists finally know why

Date:
Source:
University of California - San Diego
Summary:
Head and neck cancer, notoriously hard to treat, might have a new weakness—timing. Researchers discovered that syncing radiation and immunotherapy in just the right way can make tumors disappear in mice. By protecting the body’s immune system hubs, they’ve unlocked a potentially powerful method to fight aggressive cancers more effectively. Clinical trials are already underway, hinting at a new era in cancer treatment.

FULL STORY


Perfectly Timed Cancer Combo Wipes Out Tumors
Timed treatment wiped out tumors in mice, showing promise for hard-to-treat head and neck cancers. Credit: Shutterstock

Head and neck squamous cell carcinomas (HNSCC) are a group of cancers that affect cells in and around our mouth and nose. With 890,000 new cases and 450,000 deaths annually, HNSCC accounts for roughly 4.5% of cancer diagnoses and deaths worldwide. Treatment options for HNSCC are very limited, so nearly half of affected patients with HNSCC die from the disease. Current therapies consist of surgery, radiotherapy and chemotherapy, which can be effective but often have limited success and significant side effects.

To meet this unmet medical need, researchers at the University of California San Diego School of Medicine are exploring new approaches to improve the effectiveness of treatments for HNSCC. In a new study of oral cancer, a type of HNSCC, they demonstrate how precisely timing two different treatments can potentially improve treatment outcomes by protecting tumor-draining lymph nodes, which are located close to tumors and have an important role in mediating the immune system's response to the tumor.

The researchers found:

  • In mice with oral cancer, delivering radiation therapy that preserves tumor-draining lymph nodes then later delivering immunotherapy resulted in a complete and durable tumor response, meaning the tumors became undetectable. This happened in 15/20 mice treated with this approach.
  • The two treatments synergized to enhance migration of a specific type of immune cell, called activated CCR7+ dendritic cells, from tumors into lymph nodes. These cells helped trigger a stronger immune response to the tumor. This occurred in all treated mice.

The study's results could have significant implications for the treatment of HNSCC, as well as other cancers that are resistant or unresponsive to current standard treatment approaches. The research also provides valuable biological insight into the role of tumor-draining lymph nodes in cancer biology, which could have further implications for developing new therapies. While it will take further research to fully explore the potential of this timed treatment approach, the findings demonstrate the importance of optimizing the sequence and timing of therapies to maximize their benefit to the patient. The researchers are now conducting clinical trials in collaboration with investigators at Providence Earl Chiles Cancer Center to leverage these strategies to improve outcomes in head and neck cancer patients.

The study, published in Nature Communications, was led by Robert Saddawi-Konefka, M.D., Ph.D.,PGY-8, resident physician and Joseph Califano, M.D., professor and interim chair in the Department of Otolaryngology and Iris and Matthew Strauss Chancellor's Endowed Chair in Head and Neck Surgery at UC San Diego School of Medicine. Califano is also director of the Hanna and Mark Gleiberman Head and Neck Cancer Center at Moore's Cancer Center. The study was supported, in part by a National Cancer Institute funded R01 grant led by. Califano and Andrew Sharabi, M.D., Ph.D., associate professor and Jacobs Chancellor's Endowed Chair in the Department of Radiation Medicine and Applied Sciences at UC San Diego School of Medicine, as well as a member of the Head and Neck Cancer Center at Moores Cancer Center. The authors declare no competing interests.


Story Source:

Materials provided by University of California - San Diego. Note: Content may be edited for style and length.


Journal Reference:

  1. Robert Saddawi-Konefka, Riyam Al Msari, Shiqi Tang, Chad Philips, Sayed Sadat, Lauren M. Clubb, Sarah Luna, Santiago Fassardi, Riley Jones, Ida Franiak Pietryga, Farhoud Faraji, Shiruyeh Schokrpur, Bryan S. Yung, Michael M. Allevato, Kelsey E. Decker, Chanond A. Nasamran, Daisy Chilin-Fuentes, Sara Brin Rosenthal, Shawn M. Jensen, Bernard A. Fox, R. Bryan Bell, J. Silvio Gutkind, Andrew Sharabi, Joseph A. Califano. The tumor-sentinel lymph node immuno-migratome reveals CCR7⁺ dendritic cells drive response to sequenced immunoradiotherapy. Nature Communications, 2025; 16 (1) DOI: 10.1038/s41467-025-61780-4[1]

Cite This Page:

University of California - San Diego. "Perfectly timed cancer combo wipes out tumors by supercharging the immune system." ScienceDaily. ScienceDaily, 4 August 2025. <www.sciencedaily.com/releases/2025/08/250803233100.htm>.

University of California - San Diego. (2025, August 4). Perfectly timed cancer combo wipes out tumors by supercharging the immune system. ScienceDaily. Retrieved August 4, 2025 from www.sciencedaily.com/releases/2025/08/250803233100.htm

University of California - San Diego. "Perfectly timed cancer combo wipes out tumors by supercharging the immune system." ScienceDaily. www.sciencedaily.com/releases/2025/08/250803233100.htm (accessed August 4, 2025).

RELATED STORIES


Breakthrough: How Radiation Helps the Immune System Kill Cancer[2]

July 23, 2025 — Radiation therapy, once thought of mainly as a local cancer treatment, is now showing power to awaken the immune system in surprising ways. Researchers discovered that combining radiation with ...

New Blood Test Shows Superior Sensitivity in Detecting HPV-Associated Head and Neck Cancers[3]

May 20, 2025 — Head and neck cancer researchers are reporting the development and testing of HPV-DeepSeek, a novel liquid biopsy assay. In their new study, HPV-DeepSeek achieved 99% sensitivty and specifity for ...

Study Identifies How Ovarian Cancer Protects Itself, Paves Way for Improved Immunotherapy Approach[4]

Oct. 30, 2024 — Researchers have discovered a way that ovarian cancer tumors manipulate their environment to resist immunotherapy and identified a drug target that could overcome that resistance. The study used a ...

Experimental mRNA Cancer Vaccine Shows Potential for Advanced Stage Cancer Patients in Phase 1 Trial[5]

Sep. 13, 2024 — Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers. The investigational mRNA cancer immunotherapy is ...

Why Cancer Immunotherapies Don't Work for Everyone[6]

Jan. 24, 2024 — Scientists uncovered a mechanism by which cancer cells prevent the immune system from activating and attacking the cancerous invaders. The study sheds light on why immunotherapy treatments don't ...

Immunotherapy for HPV+ Head and Neck Cancer: Awakening the Force Within[7]

Sep. 1, 2021 — The immune cells that are the major targets of immune checkpoint inhibitors (stem-like PD-1+ CD8 T cells) are present in HPV+ tumors from head and neck cancer patients, according to a new study. The ...

TRENDING AT SCITECHDAILY.com[8]


Scientists Have Discovered a “Sixth Sense” That Links the Gut and Brain in Real Time[9]

Just 15 Minutes of Fast Walking a Day Could Save Your Life, New Study Finds[10]

“Living Fossil” Just Shattered 70 Years of Evolutionary Assumptions[11]

It Shouldn’t Exist: Astronomers Discover a Planet Orbiting the “Wrong Way”[12]

Read more …Perfectly timed cancer combo wipes out tumors by supercharging the immune system

More Articles …